Abstract: The disclosure is directed to a coding RNA encoding an antigenic polypeptide which is selected or derived from Escherichia coli FimH. The present disclosure is also directed to compositions and vaccines comprising said coding RNA. Further, the disclosure concerns a kit, particularly a kit of parts comprising the coding RNA, or the composition, or the vaccine. The disclosure is also directed to methods of treating or preventing a disorder caused by E. coli.

Abstract: The present invention is directed to novel, modified FimH polypeptides, nucleic acids encoding them, and the use of the polypeptides and nucleic acids in the treatment and/or prevention of disease, in particular, urinary tract infection (UTI).

Abstract: The present invention is direct to isolated polypeptides comprising or consisting of: an amino acid sequence selected from the group consisting of SEQ ID NOs: 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47 or 48; or (a) a variant and/or fragment of (a), for example: (i) a variant of (a); (ii) a fragment of (a); or (iii) a variant of a fragment of (a); together with corresponding isolated nucleic acid molecules, vectors, host cells, methods of production, vesicles, binding moieties, pharmaceutical compositions, kits, methods of treatment and medical uses.

Abstract: Chimeric capsular polysaccharides, conjugates comprising such chimeric capsular polysaccharides, and pharmaceutical compositions thereof. Further aspects include methods for immunising a subject against infection by administration of such polysaccharides, conjugates, or compositions.